SFTPA2 and asthma: SP-A is also known to modulate cytokines, IgE and eosinophil levels in the setting of type 2-associated allergic inflammation17,18 and treatment with exogenous SP-A in mouse models of asthma significantly reduces tissue eosinophilia19.